Compare
Lexeo Therapeutics, Inc. vs Tectonic Therapeutic, Inc. vs Invivyd, Inc. vs Voyager Therapeutics, Inc.
| Latest fiscal year | Lexeo Therapeutics, Inc. LXEO | Tectonic Therapeutic, Inc. TECX | Invivyd, Inc. IVVD | Voyager Therapeutics, Inc. VYGR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $53.43M | $40.37M |
| Revenue growth (YoY) | n/a | n/a | +110.5% | -49.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -104.0% | -326.6% |
| Net margin | n/a | n/a | -98.2% | -296.5% |
| Net income | -$99.96M | -$74.15M | -$52.49M | -$119.72M |
| EPS (Diluted) | -$1.86 | -$4.05 | -$0.30 | -$2.04 |
| Operating cash flow | -$98.56M | -$60.08M | -$58.13M | -$132.47M |
| Free cash flow | -$98.96M | -$60.29M | -$58.29M | -$135.06M |
| Cash & equivalents | $63.00M | $253.80M | $226.69M | $65.30M |
| Total assets | $268.69M | $261.04M | $276.88M | $252.28M |
| Total liabilities | $22.02M | $9.71M | $35.34M | $56.20M |
| Shareholders' equity | $246.67M | $251.33M | $241.54M | $196.08M |
| Return on year-end equity | -40.5% | -29.5% | -21.7% | -61.1% |
| Shares outstanding | 73.00M | 18.74M | 281.99M | 59.05M |
Revenue, most recent five fiscal years
| Fiscal year | Lexeo Therapeutics, Inc. | Tectonic Therapeutic, Inc. | Invivyd, Inc. | Voyager Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $654.0K Ended 2022-12-31 | n/a | $53.43M Ended 2025-12-31 | $40.37M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $25.38M Ended 2024-12-31 | $80.00M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $250.01M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $40.91M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $37.41M Ended 2021-12-31 |